As any pet owner can attest, when a dog stops eating it can be a source of major concern. With its recently approved product for dogs, Entyce, Aratana Therapeutics ...
ENTYCE Provides the First Therapeutic Based on the Natural Physiology of Appetite Commenting on the launch, Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics, stated that ...
The US Food and Drug Administration's Center for Veterinary Medicine (CVM) has approved Aratana Therapeutics' Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in ...
LEAWOOD, Kan., May 17, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative ...
Aratana Therapeutics reports encouraging revenue from Galliprant. The company inks stock placement deal to improve liquidity. Aratana Therapeutics seeks to fix ENTYCE issues. Aratana Therapeutics Inc.
Aratana Therapeutics ($PETX) has been promising investors three regulatory approvals this year, and now it’s two-thirds of the way toward reaching that goal. On May ...
Good morning and welcome to the Aratana Therapeutics Third Quarter 2017 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback